Ftse Mib
34.402,25
0,25%
DAX
20.271,01
0,09%
S&P 500
6.050,61
-0,39%
NASDAQ
20.109,06
-0,32%
Bitcoin
103.975,52
-2,05%
Pepperstone
Advertisement
Registration Strip Icon for default Registrati gratuitamente per ottenere quotazioni in tempo reale, grafici interattivi, flusso di opzioni in tempo reale e altro ancora.
Registrati

Quotazioni in diretta

Non abbiamo trovato risultati per:
Assicurati di aver scritto correttamente o prova ad allargare la ricerca.

Più Attivi

Toplist

Sembra che tu non sia connesso.
Clicca il pulsante qui sotto per accedere e visualizzare la tua cronologia recente.

Registrati

Sei già registrato? Accedi

Pepperstone

Inizia Ora

Pepperstone
Home Investire Azioni U.S.A. NASDAQ Windtree Therapeutics Inc (WINT) Windtree Therapeutics Inc (WINT) Notizie

WINT

Windtree Therapeutics (WINT)

HOME News News di Agenzia

News di Agenzia

Da:
 Ti mostriamo gli articoli più rilevanti per la tua ricerca:NASDAQ:WINT
DataOraFonteTitoloSimboloCompagnia
16/12/202414:00GlobeNewswire Inc.Windtree Announces Istaroxime Presentation By Cardiogenic Shock Thought Leader At Cardiovascular Clinical Trials ConferenceNASDAQ:WINTWindtree Therapeutics Inc
09/12/202414:00GlobeNewswire Inc.Windtree Announces New Istaroxime Patent Filing for Preventing or Reducing the Risk of Acute Myocardial ArrhythmiaNASDAQ:WINTWindtree Therapeutics Inc
05/12/202413:12Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:WINTWindtree Therapeutics Inc
04/12/202414:00GlobeNewswire Inc.Windtree Announces Partnership with New Growth Advisors to Leverage Positive Phase 2 Istaroxime Study in Cardiogenic Shock for a Potential Strategic TransactionNASDAQ:WINTWindtree Therapeutics Inc
27/11/202422:05GlobeNewswire Inc.Windtree Therapeutics Reports Third Quarter 2024 Financial Results and Provides Key Business UpdatesNASDAQ:WINTWindtree Therapeutics Inc
14/11/202414:53Edgar (US Regulatory)Form SC 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]NASDAQ:WINTWindtree Therapeutics Inc
14/11/202414:00GlobeNewswire Inc.Windtree Announces Leadership Transition Plan With Industry VeteransNASDAQ:WINTWindtree Therapeutics Inc
04/11/202414:00GlobeNewswire Inc.Windtree Announces Expansion of Patents with Issuance of Istaroxime Patent for Hong KongNASDAQ:WINTWindtree Therapeutics Inc
30/10/202413:00GlobeNewswire Inc.Windtree Therapeutics Initiates SEISMiC C Study of Istaroxime in SCAI Stage C Cardiogenic Shock for Planned Completion of Phase 2b and Transition to Phase 3NASDAQ:WINTWindtree Therapeutics Inc
23/10/202414:00GlobeNewswire Inc.Windtree Announces Istaroxime Cardiogenic Shock Patent Filings In Countries Around the WorldNASDAQ:WINTWindtree Therapeutics Inc
21/10/202414:00GlobeNewswire Inc.Windtree To Present at the ThinkEquity Conference on October 30thNASDAQ:WINTWindtree Therapeutics Inc
17/10/202414:15GlobeNewswire Inc.Windtree Announces Expansion of Patents with Issuance of Istaroxime Patent for JapanNASDAQ:WINTWindtree Therapeutics Inc
09/10/202414:00GlobeNewswire Inc.Windtree Announces Publication of Positive Istaroxime Phase 2b Study Trial DesignNASDAQ:WINTWindtree Therapeutics Inc
09/10/202413:46Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:WINTWindtree Therapeutics Inc
30/09/202414:15GlobeNewswire Inc.Windtree Announces Positive Phase 2b Topline Clinical Results with Istaroxime Significantly Improving Cardiac Function and Blood Pressure in Heart Failure Patients in Early Cardiogenic ShockNASDAQ:WINTWindtree Therapeutics Inc
26/09/202422:05GlobeNewswire Inc.Windtree Therapeutics Announces Virtual Investor Day Presentation on October 1 at 3pm ETNASDAQ:WINTWindtree Therapeutics Inc
25/09/202414:15GlobeNewswire Inc.Windtree Announces Positive Topline Results from Its Phase 2b SEISMiC Extension Study of Istaroxime in Early Cardiogenic ShockNASDAQ:WINTWindtree Therapeutics Inc
04/09/202414:00GlobeNewswire Inc.Windtree Completes Enrollment of Phase 2b Study of Istaroxime in Early Cardiogenic ShockNASDAQ:WINTWindtree Therapeutics Inc
04/09/202406:15Edgar (US Regulatory)Form EFFECT - Notice of EffectivenessNASDAQ:WINTWindtree Therapeutics Inc
03/09/202415:10Edgar (US Regulatory)Form 424B5 - Prospectus [Rule 424(b)(5)]NASDAQ:WINTWindtree Therapeutics Inc
03/09/202413:26Edgar (US Regulatory)Form ARS - Annual Report to Security HoldersNASDAQ:WINTWindtree Therapeutics Inc
03/09/202413:22Edgar (US Regulatory)Form DEF 14A - Other definitive proxy statementsNASDAQ:WINTWindtree Therapeutics Inc
23/08/202422:15Edgar (US Regulatory)Form S-1 - General form for registration of securities under the Securities Act of 1933NASDAQ:WINTWindtree Therapeutics Inc
21/08/202422:55Edgar (US Regulatory)Form S-3 - Registration statement under Securities Act of 1933NASDAQ:WINTWindtree Therapeutics Inc
20/08/202422:05GlobeNewswire Inc.Windtree Therapeutics Reports Second Quarter 2024 Financial Results and Provides Key Business UpdatesNASDAQ:WINTWindtree Therapeutics Inc
19/08/202423:06Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:WINTWindtree Therapeutics Inc
14/08/202422:24Edgar (US Regulatory)Form 3 - Initial statement of beneficial ownership of securitiesNASDAQ:WINTWindtree Therapeutics Inc
14/08/202422:11Edgar (US Regulatory)Form NT 10-Q - Notification of inability to timely file Form 10-Q or 10-QSBNASDAQ:WINTWindtree Therapeutics Inc
14/08/202422:05GlobeNewswire Inc.Windtree Announces New Additions and Changes to Its Board of DirectorsNASDAQ:WINTWindtree Therapeutics Inc
25/07/202422:07Edgar (US Regulatory)Form RW - Registration Withdrawal RequestNASDAQ:WINTWindtree Therapeutics Inc
 Ti mostriamo gli articoli più rilevanti per la tua ricerca:NASDAQ:WINT

La tua Cronologia

BIT
ENI
Eni
BIT
UCG
Unicredit
BIT
TIT
Telecom Italia
BIT
ISP
Intesa Sanpaolo
BIT
STLAM
Stellantis NV
BIT
BPE
Bper Banca
BIT
BAMI
Banco BPM
BIT
ENEL
Enel
BIT
AZM
Azimut Hldg
BIT
RACE
Ferrari NV
BIT
BMPS
Banca Monte Dei Paschi D...
BIT
STMMI
ST Microelectronics
BIT
SPM
Saipem
BIT
PRY
Prysmian
BIT
FBK
Finecobank
BIT
CPR
Davide Campari
Delayed Upgrade Clock
Per accedere al tempo reale push di Borsa è necessario registrarsi.

Il sito ADVFN Italia è stato realizzato ed è gestito da PRODESFIN su licenza di ADVFN PLC.

PER CONTATTI E PUBBLICITA' SUL SITO CLICCARE QUI

Accedendo ai servizi offerti da ADVFN, ne si accettano le condizioni generali Termini & Condizioni

ADVFN Network